Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Immunogen
Immunogen
(IMGN)
ImmunoGen, Inc. (Nasdaq: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Elahere
Mirvetuximab soravtansine
2022-11-14
Fallopian tube neoplasms
,
Ovarian epithelial carcinoma
,
Peritoneal neoplasms
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Mirvetuximab soravtansine
recurrence
,
carcinoma
,
carcinosarcoma
,
hereditary breast and ovarian cancer syndrome
,
mullerian mixed tumor
,
neoplasms
,
endometrial neoplasms
,
serous cystadenocarcinoma
,
endometrioid carcinoma
,
adenocarcinoma
,
clear cell adenocarcinoma
,
acinar cell carcinoma
,
ovarian neoplasms
,
fallopian tube neoplasms
,
ovarian epithelial carcinoma
,
peritoneal neoplasms
Rucaparib
neoplasms
,
prostatic neoplasms
,
stomach neoplasms
,
peritoneal neoplasms
,
leiomyosarcoma
,
esophageal neoplasms
,
adenocarcinoma
,
carcinoma
,
endometrioid carcinoma
,
serous cystadenocarcinoma
,
endometrial neoplasms
,
fallopian tube neoplasms
,
ovarian neoplasms
,
ovarian epithelial carcinoma
Rucaparib camsylate
neoplasms
,
prostatic neoplasms
,
stomach neoplasms
,
peritoneal neoplasms
,
leiomyosarcoma
,
esophageal neoplasms
,
adenocarcinoma
,
carcinoma
,
endometrioid carcinoma
,
serous cystadenocarcinoma
,
endometrial neoplasms
,
fallopian tube neoplasms
,
ovarian neoplasms
,
ovarian epithelial carcinoma
Ado-trastuzumab emtansine
multiple myeloma
,
plasma cell neoplasms
Lampalizumab
leukemia
,
myelodysplastic syndromes
,
myeloid leukemia acute
,
neoplasms
,
myeloproliferative disorders
,
myelodysplastic-myeloproliferative diseases
,
myeloid leukemia
Etrolizumab
hiv infections
,
neoplasms
,
neoplasm metastasis
,
atrial fibrillation
Lenograstim
recurrence
,
non-hodgkin lymphoma
,
follicular lymphoma
,
large b-cell lymphoma diffuse
,
b-cell lymphoma
,
lymphoma
,
leukemia
,
myeloid leukemia acute
,
myeloid leukemia
,
myelodysplastic syndromes
,
myeloproliferative disorders
,
biphenotypic leukemia acute
,
preleukemia
,
syndrome
,
t-cell lymphoma
,
t-cell lymphoma peripheral
,
urinary bladder neoplasms
Doconexent
breast diseases
Sodium chloride
pharmacokinetics
,
healthy volunteers/patients
,
liver diseases
,
hepatocellular carcinoma
,
liver neoplasms
,
pathologic processes
,
infertility
,
brain diseases
ANETUMAB RAVTANSINE
medical sociology
,
non-small-cell lung carcinoma
,
ovarian neoplasms
,
renal insufficiency
,
oncogenes
,
neoplasms
,
adenocarcinoma
,
mesothelioma
,
lung neoplasms
,
pancreatic neoplasms
,
malignant mesothelioma
,
carcinoma
,
endometrioid carcinoma
,
serous cystadenocarcinoma
,
adenocarcinoma of lung
Bevifimod
healthy volunteers/patients
,
pneumonia
,
community-acquired infections
,
bacterial pneumonia
,
infections
,
communicable diseases
,
bacterial skin diseases
CANTUZUMAB RAVTANSINE
colorectal neoplasms
,
pancreatic neoplasms
,
stomach neoplasms
LORVOTUZUMAB MERTANSINE
multiple myeloma
,
plasma cell neoplasms
,
ovarian neoplasms
,
merkel cell carcinoma
,
lung neoplasms
,
small cell lung carcinoma
,
recurrence
,
neoplasms
,
sarcoma
,
neuroblastoma
,
synovial sarcoma
,
rhabdomyosarcoma
,
neurofibrosarcoma
,
wilms tumor
,
nerve sheath neoplasms
,
pulmonary blastoma
,
leukemia
,
hematologic neoplasms
Lotamilast
recurrence
,
non-hodgkin lymphoma
,
b-cell lymphoma marginal zone
,
follicular lymphoma
,
b-cell lymphoma
,
hearing loss
,
sensorineural hearing loss
,
deafness
,
lymphoma
NARATUXIMAB EMTANSINE
leukemia
,
b-cell chronic lymphocytic leukemia
,
lymphoid leukemia
,
non-hodgkin lymphoma
,
lymphoma
,
large b-cell lymphoma diffuse
,
b-cell lymphoma
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use